Article
type: Class

Document
type: Class

Anualidad
type: Class

Academic Article
type: Class

Information Content Entity
type: Class

Continuant
type: Class

Entity
type: Class

2023
type: Class

Generically Dependent Continuant
type: Class

individual
type: Document
rights: termsOfUse
date: 2026-08-16T16:49:21
publisher: Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24¿weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group
label: RDF description of Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24¿weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group - http://research.umh.es/vivo/pub/articulo/256498

Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24¿weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group
type: Information Content Entity
related by: AutorExt:400060_2023-Artículo:256498
related by: AutorExt:400040_2023-Artículo:256498
related by: AutorExt:400044_2023-Artículo:256498
related by: AutorExt:400084_2023-Artículo:256498
type: Entity
related by: AutorExt:400042_2023-Artículo:256498
related by: AutorExt:400043_2023-Artículo:256498
type: Generically Dependent Continuant
related by: AutorExt:400062_2023-Artículo:256498
related by: AutorExt:400039_2023-Artículo:256498
type: Thing
most specific type: 2023
related by: AutorExt:400085_2023-Artículo:256498
related by: AutorExt:400101_2023-Artículo:256498
related by: AutorExt:400063_2023-Artículo:256498
related by: AutorExt:400103_2023-Artículo:256498
most specific type: Academic Article
related by: AutorExt:400080_2023-Artículo:256498
related by: AutorExt:400082_2023-Artículo:256498
related by: AutorExt:400102_2023-Artículo:256498
related by: AutorExt:400099_2023-Artículo:256498
has publication venue: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
type: 2023
related by: AutorExt:400059_2023-Artículo:256498
included: Medicina Clínica 2023
related by: AutorExt:400104_2023-Artículo:256498
related by: AutorExt:400041_2023-Artículo:256498
related by: AutorExt:400083_2023-Artículo:256498
type: Academic Article
related by: AutorExt:400081_2023-Artículo:256498
type: Continuant
related by: AutorExt:400086_2023-Artículo:256498
date time value: 256498 pubdate
related by: AutorExt:400100_2023-Artículo:256498
type: Anualidad
related by: Autor:128480-Artículo:256498
ARG_2000028: 256498 vcard
type: Document
related by: AutorExt:400061_2023-Artículo:256498
related by: AutorExt:400079_2023-Artículo:256498
type: Article

AutorExt:400060_2023-Artículo:256498
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24¿weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

AutorExt:400040_2023-Artículo:256498
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24¿weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

AutorExt:400044_2023-Artículo:256498
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24¿weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

AutorExt:400084_2023-Artículo:256498
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24¿weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

AutorExt:400042_2023-Artículo:256498
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24¿weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

AutorExt:400043_2023-Artículo:256498
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24¿weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

AutorExt:400062_2023-Artículo:256498
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24¿weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

AutorExt:400039_2023-Artículo:256498
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24¿weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

AutorExt:400085_2023-Artículo:256498
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24¿weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

AutorExt:400101_2023-Artículo:256498
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24¿weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

AutorExt:400063_2023-Artículo:256498
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24¿weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

AutorExt:400103_2023-Artículo:256498
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24¿weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

AutorExt:400080_2023-Artículo:256498
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24¿weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

AutorExt:400082_2023-Artículo:256498
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24¿weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

AutorExt:400102_2023-Artículo:256498
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24¿weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

AutorExt:400099_2023-Artículo:256498
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24¿weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
type: Entity
type: Collection
type: Generically Dependent Continuant
type: Journal
type: Information Content Entity
type: Periodical
type: Thing
type: Continuant
publication venue for: Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24¿weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

AutorExt:400059_2023-Artículo:256498
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24¿weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

Medicina Clínica 2023
type: Anualidad
type: DepartmentReport
type: Thing
type: ResearchReport
type: 2023
includes: Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24¿weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

AutorExt:400104_2023-Artículo:256498
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24¿weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

AutorExt:400041_2023-Artículo:256498
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24¿weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

AutorExt:400083_2023-Artículo:256498
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24¿weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

AutorExt:400081_2023-Artículo:256498
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24¿weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

AutorExt:400086_2023-Artículo:256498
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24¿weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

AutorExt:400100_2023-Artículo:256498
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24¿weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

Autor:128480-Artículo:256498
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24¿weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

AutorExt:400061_2023-Artículo:256498
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24¿weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

AutorExt:400079_2023-Artículo:256498
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24¿weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group